CHIR-124

Alias: CHIR-124; CHIR 124; CHIR124
Cat No.:V1585 Purity: ≥98%
CHIR-124 (CHIR124; CHIR 124) is a novel, potent and selective quinolone-based small molecule Chk1 (Checkpoint kinase1) inhibitor with potential anticancer activity.
CHIR-124 Chemical Structure CAS No.: 405168-58-3
Product category: Chk
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

CHIR-124 (CHIR124; CHIR 124) is a novel, potent and selective quinolone-based small molecule Chk1 (Checkpoint kinase1) inhibitor with potential anticancer activity. In a cell-free assay, it inhibits Chk1 with an IC50 of 0.3 nM. The structure of CHIR-124 differs from that of other recognized Chk1 inhibitors. It exhibits 500–5,000 times less activity against CDK2/4 and Cdc2, and 2,000 times selectivity against Chk2. Based on isobologram or response surface analysis, CHIR-124 interacts synergistically with topoisomerase poisons (e.g., camptothecin and/or SN-38) to inhibit growth in a number of p53-mutant solid tumor cell lines. A new and powerful inhibitor of Chk1, CHIR-124 shows promise as an antitumor agent when combined with topoisomerase I poisons.

Biological Activity I Assay Protocols (From Reference)
Targets
Chk1 (IC50 = 0.3 nM); Chk2 (IC50 = 697.4 nM); PDGFR (IC50 = 6.6 nM); FLT3 (IC50 = 5.8 nM); Cdk4/cyclin D (IC50 = 2.05 μM); CDC2/cyclin B (IC50 = 0.5057 μM); Cdk2/cyclin A (IC50 = 0.1911 μM); bFGFR (IC50 = 2.01 μM); FGFR3 (IC50 = 1.29 μM); VEGFR2 FLK1 (IC50 = 0.5779 μM); VEGFR1 FLT1 (IC50 = 0.4636 μM); PKCα (IC50 = 0.58 μM); PKAβ I (IC50 = 2.25 μM); PKCβ II (IC50 = 0.58 μM); PKCγ (IC50 = 0.11 μM); ERK2 (IC50 = 4.31 μM); PKA (IC50 = 0.1031 μM); GSK3 (IC50 = 0.0233 μM)
ln Vitro

CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. In a range of cancer cell lines, including breast carcinoma (MDA-MB-231 and MDA-MB-435) and colon carcinoma (SW-620 and Colo205), all of which contain the mutant p53 gene, CHIR-124 plays a synergistic interaction with topoisomerase poisons (e.g., Camptothecin or SN-38) to cause growth inhibition. MDA-MD-435 breast cancer cells undergo enhanced apoptosis when CHIR-124 disrupts the S and G2-M checkpoints that are triggered by SN-38. The loss of p53 facilitates CHIR-124's induction of apoptosis and its disruption of the G2-Mcheckpoint.[1] With IC50 values of 5.8 nM and 6.6 nM, respectively, CHIR-124 also effectively targets other kinases, including PDGFR. [2]

ln Vivo
In an orthotopic breast cancer xenograft model, CHIR-124 accelerates the growth inhibitory effects of irinotecan by disrupting the G2-M checkpoint and boosting tumor apoptosis.
Enzyme Assay
The kinase domain of Sf9 insect cells is used to express the Chk1 assay, and the substrate is a biotinylated cdc25c peptide that contains the consensus Chk1/Chk2 phosphorylation site (*) (biotin-[AHX]SGSGS*GLYRSPSMP-ENLNRPR[CONH2]). A kinase reaction buffer containing 30 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM DTT, 4 mM EDTA, 25 mMβ-glycerophosphate, 5 mM MnCl2, 0.01% bovine serum albumin, 1.35 nM CHK1 kinase domain, 0.5 μM peptide substrate, 1 AM unlabeled ATP, plus 5 nM 33Pγ-labeled ATP (specific activity = 2,000 Ci/mmol) is combined with a series of CHIR-124 dilutions. A radioactive technique is used to carry out the reactions and detect the phosphate transfer. For one to four hours, reactions are incubated at room temperature. The phosphorylated peptide is then captured on microtiter plates coated with streptavidin and containing stop reaction buffer (pH 7.5, 25 mM ethylenediaminetetraacetic acid, 50 mMHEPES). Using an anti-phosphotyrosine antibody (PT66) labeled with europium, the DELFIA TRF system measures phosphorylated peptide. Using nonlinear regression and the data analysis program XL-Fit, the concentration of CHIR-124 for IC50 is determined.
Cell Assay
In log-phase, MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells are plated into 96-well microplates. Six distinct concentrations of camptothecin or 0 nM camptothecin are added to serially diluted CHIR-124. If CHIR-124 is not present, camptothecin is also serially diluted. In 96-well plates, cells are treated with CHIR-124, and they are then incubated for 48 hours at 37 °C. Every therapeutic condition is completed in three copies. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), inner salt assay is used to track cell proliferation. After adding MTS inner salt and letting the microplates sit for an additional three hours, the absorbance at 490 nm is measured using a plate reader. To create the isoboles, the drug concentrations in the combinations needed to produce 50% inhibition are plotted. The basis for isobologram analysis of drug interaction is the Loewe additivity equation (1= D A /IC50, A + DB/IC50, B), where DA and DB are the concentrations of each drug in the combination that produce 50% overall inhibition, and IC50, A and B are the concentrations of drugs to result in 50% inhibition for each drug alone. Each graph includes a diagonal line that represents Loewe additivity. Data points that lie above the line will indicate antagonism, while those that fall below the line will show synergy.
Animal Protocol
The following ten treatment groups are randomly assigned to severe combined immunodeficient mice bearing MDA-MD-435 tumor xenografts: the vehicle (captisol) by itself, 5 mg/kg CPT-11, 10 mg/kg CHIR-124, 20 mg/kg CHIR-124, 5 mg/kg CPT-11 plus 10 mg/kg CHIR-124, or 5 mg/kg CPT-11 plus 20 mg/kg CHIR-124. Day 1 (the day following randomization) is when treatment begins. CPT-11 is administered intraperitoneally (i.p.) four times a day (×5) on days 1 through 5, while CHIR-124 is administered orally four times a day ×6 in captisol on days 2 through 7. The formula for calculating percent tumor growth inhibition is T/C, where T is the treatment group mean and C is the control group mean. In a related study, tumor samples taken from mice that were sacrificed on the fourth day of treatment are analyzed for mitotic index using immunofluorescence labeling with phospho-histone H3 antibody and for apoptosis using terminal deoxynucleotidyl transferase-mediated nick-end labeling staining.
References

[1]. Clin Cancer Res . 2007 Jan 15;13(2 Pt 1):591-602.

[2]. Clin Cancer Res . 2010 Jan 15;16(2):376-83.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C23H22CLN5O
Molecular Weight
419.91
Exact Mass
419.15
Elemental Analysis
C, 65.79; H, 5.28; Cl, 8.44; N, 16.68; O, 3.81
CAS #
405168-58-3
Appearance
Solid powder
SMILES
C1CN2CCC1[C@@H](C2)NC3=C(C(=O)NC4=C3C=C(C=C4)Cl)C5=NC6=CC=CC=C6N5
InChi Key
MOVBBVMDHIRCTG-LJQANCHMSA-N
InChi Code
InChI=1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1
Chemical Name
4-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]amino]-3-(1H-benzimidazol-2-yl)-6-chloro-1H-quinolin-2-one
Synonyms
CHIR-124; CHIR 124; CHIR124
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~7 mg/mL (~16.7 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
1%DMSO+30% polyethylene glycol+1%Tween 80: 30mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3815 mL 11.9073 mL 23.8146 mL
5 mM 0.4763 mL 2.3815 mL 4.7629 mL
10 mM 0.2381 mL 1.1907 mL 2.3815 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • CHIR-124

    Synergism between topoisomerase I poisons and CHIR-124 in human cancer cell lines expressing mutant p53.2007 Jan 15;13(2 Pt 1):591-602.

  • CHIR-124

    Abrogation of cell cycle checkpoints and induction of apoptosis by CHIR-124 in MDA-MD-435 cells.2007 Jan 15;13(2 Pt 1):591-602.

  • CHIR-124

    Suppression of the Chk1 signaling pathway by CHIR-124.2007 Jan 15;13(2 Pt 1):591-602.

Contact Us